Jagati Biotech Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
- Paid Up Capital ₹ 0.10 M
- Company Age 15 Year, 11 Months
- Last Filing with ROC 31 Mar 2022
- Open Charges ₹ 1.44 M
- Revenue Growth 95.78%
- Profit Growth 200.48%
- Ebitda -22.77%
- Net Worth 31.99%
- Total Assets -3.63%
About Jagati Biotech
Jagati Biotech Private Limited (JBPL) is a Private Limited Indian Non-Government Company incorporated in India on 06 February 2009 and has a history of 15 years and 11 months. Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.44 M.
Venkateswara Tangirala and Chandrahas Veluru serve as directors at the Company.
Company Details
-
Location
Hyderabad, Telangana, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U01403TG2009PTC062736
-
Company No.
062736
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
06 Feb 2009
-
Date of AGM
30 Sep 2022
-
Date of Balance Sheet
31 Mar 2022
-
Listing Status
Unlisted
-
ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Jagati Biotech?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Venkateswara Tangirala
|
Director | 01-Jun-2019 | Current |
|
Chandrahas Veluru
|
Director | 01-Jun-2019 | Current |
Financial Performance of Jagati Biotech.
Jagati Biotech Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 95.78% increase. The company also saw a substantial improvement in profitability, with a 200.48% increase in profit. The company's net worth Soared by an impressive increase of 31.99%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Jagati Biotech?
In 2018, Jagati Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Kam Nutrione Private LimitedVenkateswara Tangirala is a mutual person
Charges (Loans)
₹1.44 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.14 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 15 Oct 2020 | Others | ₹1.44 M | Open |
How Many Employees Work at Jagati Biotech?
Unlock and access historical data on people associated with Jagati Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Jagati Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Jagati Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
